Owner Scorecard


← All companies ← IR Manual IRDM → ← IONS Pharmaceuticals IRWD →

IRD, Opus Genetics Inc.

Pharmaceuticals consumer brand Unprofitable

Opus Genetics Inc. is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases, and other types of therapies for additional ophthalmic disorders.

Opus was founded in February 2018 as Ocuphire Pharma, Inc. and has since undergone the following transactions: In April 2018, Ocuphire Pharma, Inc. merged with Ocularis Pharma, LLC, the original innovator of phentolamine mesylate ophthalmic solution.

We are also advancing Phentolamine Ophthalmic Solution 0.75%, a small-molecule therapy that is FDA-approved for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery.

Latest annual: FY2025 10-K
IRD · Opus Genetics Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$14M
+29.1% YoY
Vital signs · TTM
Cash & investments $89M
Cash burn · annual $41M
Runway 2.2 yrs

Next report By 11/13 · the 10-Q for the quarter ended late September · due within 45 days of period end · has filed ~43 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn.
What moves the needle
Operating margin has reached 46% at its best but run negative through the cycle (median −140%) — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Stock-based pay runs about 18% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2011–2025

realized figures from each filing · older years to the left
2011’112012’122013’132019’192020’202021’212022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$0$0$0$3M$0$589K$40M$19M$11M$14M$10MRevenueRevenue
61%n/m18%63%166%155%222%SG&A / revenueSG&A/rev
183%n/m36%93%244%217%392%R&D / revenueR&D/rev
($16M)($7M)($8M)($4M)($20M)($23M)$18M($11M)($62M)($39M)($51M)Operating incomeOp. inc.
−139.8%n/m45.7%−55.5%−564.7%−271.9%−513.5%Operating marginOp. mgn
($6M)($25M)($57M)$18M($10M)($58M)($50M)Pretax incomePretax
($11M)($6M)($9M)($6M)($25M)($57M)$18M($10M)($58M)($50M)($108M)Net incomeNet inc.
Cash flow & returns
($16M)($7M)($8M)($4M)($7M)($19M)$14M($1M)($26M)($35M)($41M)Operating cash flowOp. cash
$45K$42K$37K$3K$8K$4K$4K$6K$10K$53K$53KDepreciationDeprec.
($5M)($666K)$912K$2M$16M$35M($5M)$5M$29M$11M$62MWorking capital & otherWC & other
$16K$50K$25K$0CapexCapex
($16M)($8M)($4M)($7M)Owner earningsOwner earn.
($16M)($8M)($4M)($7M)Free cash flowFCF
($546K)$2M$846K($25K)$539K($100K)$0$0$1M$0Investing cash flowInv. cash
$14M$8M$12M$5M$21M$28M$4M$9M$4M$50MFinancing cash flowFin. cash
($2M)$4M$5M$1M$15M$8M$18M$8M($20M)$15MChange in cashΔ cash
-106%-65%-75%-255%39%-20%-856%-323%Return on equityROE
−106%−65%−75%−255%39%−20%−856%−323%Retained to equityRetained/eq
Balance sheet
$12M$14M$19M$15M$16M$25M$43M$51M$30M$45M$89MCash & investmentsCash+inv
$0$1M$926K$4M$2M$1MReceivablesReceiv.
$1M$852K$934K$342K$1M$2M$1M$2M$3M$3M$2MAccounts payablePayables
($2M)$229K($1M)$415K($1M)($840K)Operating working capitalOper. WC
$12M$14M$19M$2M$18M$26M$49M$54M$37M$50M$93MCurrent assetsCur. assets
$9M$3M$4M$3M$4M$11M$8M$8MCurrent liabilitiesCur. liab.
0.2×5.5×6.8×17.8×13.3×3.2×6.4×12.2×Current ratioCurr. ratio
$95K$52K$65K$22K$14K$10K$6K$0$252K$199KNet PP&ENet PP&E
$14M$15M$20M$2M$18M$26M$49M$54M$37M$50M$93MTotal assetsAssets
$0$1M$35MTotal debtDebt
($30M)($44M)($54M)Net debt / (cash)Net debt
-3.0×-2.9×-11352.5×2025.1×-299.2×-186.1×Interest coverageInt. cov.
$3M$5M$7M$9M$31M$4M$3M$4M$11M$35MTotal liabilitiesTotal liab.
$11M$10M$13M($8M)($13M)$22M$46M$50M$7M$15M($13M)Shareholders’ equityEquity
10.3%325.0%4.5%18.4%30.6%23.9%45.3%Stock comp / revenueSBC/rev
Per share
93.0M97.1M129M2.8M4.7M14.9M20.6M21.6M26.7M62.2M91.2MShares out (diluted)Shares
$0.00$0.00$0.00$1.05$0.00$0.04$1.93$0.88$0.41$0.23$0.11Revenue / shareRev/sh
$-0.12$-0.06$-0.07$-2.17$-5.28$-3.82$0.87$-0.46$-2.15$-0.80$-1.18EPS (diluted)EPS
$-0.17$-0.06$-1.27$-1.46Owner earnings / shareOE/sh
$-0.17$-0.06$-1.27$-1.46Free cash flow / shareFCF/sh
$0.00$0.00$0.01$0.00Cap. spending / shareCapex/sh
$0.12$0.10$0.10$-2.66$-2.89$1.50$2.24$2.31$0.25$0.25$-0.14Book value / shareBVPS

The diluted share count moved ×1/45.22 into 2019 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1.64 into 2020 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×3.19 into 2021 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×2.33 into 2025 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1.47 into TTM — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2020 the business turned a $25M loss into ($7M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

FY2020FY2019FY2013FY2011
Reported net income($25M)($6M)($9M)($11M)
Depreciationnon-cash charge added back+$8K+$3K+$37K+$45K
Stock-based compensationreal costnon-cash, but a real cost+$2M+$308K+$565K+$639K
Working capital & othertiming of cash in and out, other non-cash items+$16M+$2M+$912K−$5M
Cash from operations($7M)($4M)($8M)($16M)
Capital expenditurecash put back in to keep running and to grow−$25K−$50K−$16K
Owner earnings($7M)($4M)($8M)($16M)
Owner-earnings marginowner earnings ÷ revenue-121%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $2M), owner earnings is nearer ($8M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income ($39M) ÷ interest expense $129K
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash $45M − debt $1M
    What this means

    Cash and short-term investments exceed every dollar of debt by $44M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Not meaningful here
    Invested capital ($29M) = debt $1M + equity $15M − cash
    Industry peers: median -86%
    What this means

    Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.

  • Not enough data
    Industry peers: median -422%
    What this means

    The filing data didn't include the inputs for this check.

  • Loss, and burning cash
    Net income ($50M) · cash from operations ($35M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting?
    Not enough data
    What this means

    The filing data didn't include the inputs for this check.

The promise and the pay packet

  • Is the buyback buying ownership, or mopping up? 23.9%
    Stock pay, share count unread
    Stock compensation $3M (fiscal 2025), 23.9% of revenue · no repurchases · the share count is not comparable across these years (a split or a first listing sits in the record), so the drift is withheld
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 2 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $14M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 6.43×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $1M vs $42M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 9 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.47/share (latest year $-0.60), the averaged base the calculator's gate runs on, and book value is $0.18/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2011–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 1 of 10
    What this means

    Lost money in 9 year(s), look at what happened there before trusting the average.

  • Operating margin −1316% → −297% (3-yr avg ends)

    In the filing’s words The record and the words agree: the margin widened and the filing attributes the gain to its own pricing, not volume alone.

    What this means

    Through the cycle the operating margin widened — about −1316% early to −297% lately, median −272% — pricing power intact or improving.

  • Worst year 2021 · −3854.8% op. margin
    What this means

    Operations went underwater in 2021, understand why before trusting the good years.

  • Share count −2.8%/yr
    What this means

    The share count is shrinking, buybacks are quietly growing your slice of the business.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$93M
  • Cash & short-term investments$89M
  • Receivables$1M
  • Other current assets$3M
Current liabilities$8M
  • Accounts payable$2M
  • Other current liabilities$6M
Current ratio12.19×all current assets ÷ what's due · Graham looked for 2×
Quick ratioinventory untagged this quarter, so withheld rather than shown equal to the current ratio
Cash ratio11.68×strictest: cash alone against what's due
Working capital$85Mthe cushion left after near-term bills
Cash runway2.2 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago−73.8%the freshest read on whether the business is still growing
Current ratio, recent quarters6.6× → 12.2×
Deeper floors
Tangible book value($13M)equity stripped of goodwill & intangibles
Net current asset value($13M)Graham's net-net: current assets less all liabilities
Debt incl. operating leases$35Mno operating-lease liability tagged this quarter, so debt alone

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid.

  • Insider ownership<1%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$3M

    The slice of the business handed to employees in shares in fiscal 2025, 23.9% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
SLGLSol-Gel Technologies Ltd.$19M-108.7%-49%-111%
QUREuniQure N.V.$16M94%-334.3%-87%-379%
IVAInventiva S.A.$16M-468.9%3y-396%
IRDOpus Genetics Inc.$14M-139.8%-506%2y-121%1y
ABUSArbutus Biopharma Corporation$14M-430.5%-85%-479%
EVMNEvommune Inc.$13M-623.6%1y-40%1y-590%1y
PRLDPrelude Therapeutics Incorporated$12M-861.3%1y-170%2y-464%1y
CBIOCrescent Biopharma Inc.$11M-74.1%-1404%1y-71%
Group median-382.4%-129%-379%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

The owner-earnings base could not be formed from this filing’s tagged data (operating cash flow or capital spending is missing), so the owner-earnings reverse-DCF has no base to grow. We read the price from both ends instead: type a price to see the profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered−31%/yr’20→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Opus Genetics Inc. (IRD), the owner's record," https://ownerscorecard.com/c/IRD, data as of 2026-08-17.

Manual order: ← IR its page in the Manual IRDM →

Industry order: ← IONS the Pharmaceuticals chapter IRWD →